An Update on Primary Central Nervous System Lymphoma

Hematology/Oncology Clinics of North America

Volumn 20, Issue 6, 2006, Pages 1267-1285

  Iwamoto, Fabio M ^a   DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GADOLINIUM; HYDROCORTISONE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MOLECULAR MARKER; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TENIPOSIDE; THIOTEPA; TOPOTECAN; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ATAXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN ATROPHY; BRAIN EDEMA; BRAIN INFECTION; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID CYTOLOGY; CEREBROVASCULAR DISEASE; CHEMOSENSITIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DEMYELINATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EYE TUMOR; GLIOSIS; HUMAN; HYPEROSMOLARITY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INCONTINENCE; LEPTOMENINX; LEUKOENCEPHALOPATHY; LUMBAR PUNCTURE; LYMPHOMA; MEMORY DISORDER; MENINGITIS; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOMOTOR DISORDER; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SEIZURE; SEROLOGY; SLIT LAMP; STROKE; SURVIVAL; TREATMENT OUTCOME; TUMOR DIAGNOSIS; TUMOR GROWTH; UNITED STATES; UNSPECIFIED SIDE EFFECT;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PROGNOSIS;

EID: 33750942875     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.09.002     Document Type: Review

References (81)

1. Olson J.E., Janney C.A., Rao R.D., et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95 (2002) 1504-1510
2. Fine H.A., and Mayer R.J. Primary central nervous system lymphoma. Ann Intern Med 119 (1993) 1093-1104
3. Panageas K.S., Elkin E.B., DeAngelis L.M., et al. Trends in survival from primary central nervous system lymphoma, 1975-1999. Cancer 104 (2005) 2466-2472
4. Kadan-Lattick N.S., Skluzacek M.C., and Gurney J.G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95 (2002) 193-202
5. Sacktor N., Lyles R.H., Skolasky R., et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56 (2001) 257-260
6. Besson C., Goubar A., Gabarre J., et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98 (2001) 2339-2344
7. Wolf T., Brodt H.R., Fischtlscherer S., et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 46 (2005) 207-215
8. Anthony I.C., Crawford D.H., and Bell J.E. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 126 (2003) 1058-1067
9. Smith J.R., Braziel R.M., Paoletti S., et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101 (2003) 815-821
10. Krumbholz M., Theil D., Derfuss T., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201 (2005) 195-200
11. Jahnke K., Coupland S.E., Na I.K., et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Blood 106 (2005) 384-385
12. Bataille B., Delwail V., Menet E., et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92 (2000) 261-266
13. Lachance D.H., O'Neill B.P., Macdonald D.R., et al. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 41 (1991) 95-100
14. Balmaceda C., Gaynor J.J., Sun M., et al. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 38 (1995) 202-209
15. Peterson K., Gordon K.B., Heinemann M.H., et al. The clinical spectrum of ocular lymphoma. Cancer 72 (1993) 843-849
16. Ferreri A.J., Blay J.Y., Reni M., et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13 (2002) 531-538
17. Hormigo A., Abrey L., Heinemann M., et al. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126 (2004) 202-208
18. Kawasaki K., Wakabayashi K., Koizumi T., et al. Spinal cord involvement of primary central nervous system lymphomas: histopathological examination of 14 autopsy cases. Neuropathology 22 (2002) 13-18
19. Bekar A., Cordan T., Evrensel T., et al. A case of primary spinal intramedullary lymphoma. Surg Neurol 55 (2001) 261-264
20. Buhring U., Herrlinger U., Krings T., et al. MRI features of primary central nervous system lymphomas at presentation. Neurology 57 (2001) 393-396
21. Kuker W., Nagele T., Korfel A., et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72 (2005) 169-177
22. Abrey L.E., Batchelor T.T., Ferreri A.J., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23 (2005) 5034-5043
23. Miller D.M., Hochberg F.H., Harris N.L., et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma: the Massachusetts General Hospital experience 1958-1989. Cancer 74 (1994) 1383-1397
24. Camilleri-Broet S., Martin A., Moreau A., et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Am J Clin Pathol 110 (1998) 607-612
25. Shenkier T.N., Blay J.Y., O'Neill B.P., et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group. J Clin Oncol 23 (2005) 2233-2239
26. Ferreri A.J., Reni M., Pasini F., et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 58 (2002) 1513-1520
27. Hayabuchi N., and Shibamoto Y. Onizuka Y. Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys 44 (1999) 265-272
28. Ferreri A.J., Blay J.Y., Reni M., et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21 (2003) 266-272
29. Corry J., Smith J.G., Wirth A., et al. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41 (1998) 615-620
30. Abrey L.E., Yahalom J., and DeAngelis L.M. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18 (2000) 3144-3150
31. Bessell E.M., Graus F., Lopez-Guillermo A., et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59 (2004) 501-508
32. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
33. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
34. Larocca L.M., Capello D., Rinelli A., et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 92 (1998) 1011-1019
35. Braaten K.M., Betensky R.A., de Leval L., et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9 (2003) 1063-1069
36. Camilleri-Broet S., Criniere E., Broet P., et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107 1 (2006) 190-196
37. O'Neill B.P., O'Fallon J.R., Earle J.D., et al. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?. Int J Radiat Oncol Biol Phys 33 (1995) 663-673
38. Schultz C., Scott C., Sherman W., et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 14 (1996) 556-564
39. Mead G.M., Bleehen N.M., Gregor A., et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 89 (2000) 556-564
40. Ferreri A.J., Abrey L.E., Blay J.Y., et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21 (2003) 2407-2414
41. Shibamoto Y., Ogino H., Hasegawa M., et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62 (2005) 809-813
42. Lai R., Rosenblum M.K., and DeAngelis L.M. Primary CNS lymphoma: a whole-brain disease?. Neurology 59 (2002) 1557-1562
43. Shibamoto Y., Hayabuchi N., Hiratsuka J., et al. Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97 (2003) 128-133
44. Nelson D.F., Martz K.L., Bonner H., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23 (1992) 9-17
45. Bessell E.M., Lopez-Guillermo A., Villa S., et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20 (2002) 231-236
46. DeAngelis L.M., Seiferheld W., Schold S.C., et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20 (2002) 4643-4648
47. Fisher B., Seiferheld W., Schultz C., et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 74 (2005) 201-205
48. DeAngelis L.M., Yahalom J., Thaler H.T., et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10 (1992) 635-643
49. Omuro A.M., DeAngelis L.M., Yahalom J., et al. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64 (2005) 69-74
50. O'Brien P., Roos D., Pratt G., et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18 (2000) 519-526
51. Glass J., Gruber M.L., Cher L., et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81 (1994) 188-195
52. Ferreri A.J., Reni M., Dell'Oro S., et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology 60 (2001) 134-140
53. Poortmans P.M., Kluin-Nelemans H.C., Haaxma-Reiche H., et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial 20962. J Clin Oncol 21 (2003) 4483-4488
54. Freilich R.J., Delattre J.Y., Monjour A., et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46 (1996) 435-439
55. Sandor V., Stark-Vancs V., Pearson D., et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16 (1998) 3000-3006
56. Cheng A.L., Yeh K.H., Uen W.C., et al. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 82 (1998) 1946-1951
57. Hoang-Xuan K., Taillandier L., Chinot O., et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21 (2003) 2726-2731
58. Pels H., Schmidt-Wolf I.G., Glasmacher A., et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21 (2003) 4489-4495
59. Batchelor T., Carson K., O'Neill A., et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21 (2003) 1044-1049
60. Herrlinger U., Schabet M., Brugger W., et al. German Cancer Society Neuro-oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51 (2002) 247-252
61. Herrlinger U., Kuker W., Uhl M., et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57 (2005) 843-847
62. Kraemer D.F., Fortin D., Doolittle N.D., et al. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 48 (2001) 1033-1040
63. Khan R.B., Shi W., Thaler H.T., et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 58 (2002) 175-178
64. Batchelor T.T., Kolak G., Ciordia R., et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9 (2003) 711-715
65. Abrey L.E., Moskowitz C.H., Mason W.P., et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21 (2003) 4151-4156
66. Brevet M., Garidi R., Gruson B., et al. First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 75 (2005) 288-292
67. Cheng T., Forsyth P., Chaudhry A., et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 31 (2003) 679-685
68. Soussain C., Suzan F., Hoang-Xuan K., et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19 (2001) 742-749
69. Reni M., Ferreri A.J., and Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79 (1999) 530-534
70. Nguyen P.L., Chakravarti A., Finkelstein D.M., et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23 (2005) 1507-1513
71. Plotkin S.R., Betensky R.A., Hochberg F.H., et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10 (2004) 5643-5646
72. Pels H., Montesinos-Rongen M., Schaller C., et al. Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. Neurology 63 (2004) 167-169
73. Enting R.H., Demopoulos A., DeAngelis L.M., et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 (2004) 901-903
74. Reni M., Mason W., Zaja F., et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40 (2004) 1682-1688
75. Arellano-Rodrigo E., Lopez-Guillermo A., Bessell E.M., et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70 (2003) 219-224
76. Fischer L., Thiel E., Klasen H.A., et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62 (2004) 1885-1887
77. Herrlinger U., Brugger W., Bamberg M., et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54 (2000) 1707-1708
78. Omuro A.M., Ben-Porat L.S., Panageas K.S., et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62 (2005) 1595-1600
79. Lai R., Abrey L.E., Rosenblum M.K., et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62 (2004) 451-456
80. Shenkier T.N., Voss N., Chanabhai M., et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Cancer 103 (2005) 1008-1017
81. Shibamoto Y., Tsuchida E., Seki K., et al. Primary central nervous system lymphoma in Japan 1995-1999:changes from the preceding 10 years. J Cancer Res Clin Oncol 130 (2004) 351-356